Prolonged vs intermittent intravenous infusion of β-lactam antibiotics for patients with sepsis: a systematic review of randomized clinical trials with meta-analysis and trial sequential analysis

[1] Bauer M(2020)Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019- results from a systematic review and meta-analysis Crit Care 24 239-211

[2] Gerlach H(2020)Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the global burden of disease study Lancet 395 200-444

[3] Vogelmann T(2023)Surviving sepsis campaign Crit Care Med 51 431-1000

[4] Preissing F(2018)The surviving sepsis campaign bundle: 2018 update Crit Care Med 46 997-1639

[5] Stiefel J(2021)beta-Lactam antibiotic targets and resistance mechanisms: from covalent inhibitors to substrates RSC Med Chem 12 1623-10

[6] Adam D(1998)Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1-1083

[7] Rudd KE(2014)DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58 1072-510

[8] Johnson SC(2018)Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients Crit Care 22 233-1247

[9] Agesa KM(2020)Prolonged infusion of beta-lactam antibiotics for gram-negative infections: rationale and evidence base Curr Opin Infect Dis 33 501-120

[10] Shackelford KA(2021)Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 Intensive Care Med 47 1181-151

[1] Bauer M(2020)Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019- results from a systematic review and meta-analysis Crit Care 24 239-211

[2] Gerlach H(2020)Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the global burden of disease study Lancet 395 200-444

[3] Vogelmann T(2023)Surviving sepsis campaign Crit Care Med 51 431-1000

[4] Preissing F(2018)The surviving sepsis campaign bundle: 2018 update Crit Care Med 46 997-1639

[5] Stiefel J(2021)beta-Lactam antibiotic targets and resistance mechanisms: from covalent inhibitors to substrates RSC Med Chem 12 1623-10

[6] Adam D(1998)Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1-1083

[7] Rudd KE(2014)DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58 1072-510

[8] Johnson SC(2018)Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients Crit Care 22 233-1247

[9] Agesa KM(2020)Prolonged infusion of beta-lactam antibiotics for gram-negative infections: rationale and evidence base Curr Opin Infect Dis 33 501-120

[10] Shackelford KA(2021)Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 Intensive Care Med 47 1181-151